Phathom Pharmaceuticals (PHAT) Competitors $6.96 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PHAT vs. IRON, BLTE, IBRX, WVE, ARQT, INDV, GLPG, AKRO, DYN, and IMCRShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Disc Medicine (IRON), Belite Bio (BLTE), ImmunityBio (IBRX), Wave Life Sciences (WVE), Arcutis Biotherapeutics (ARQT), Indivior (INDV), Galapagos (GLPG), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Disc Medicine Belite Bio ImmunityBio Wave Life Sciences Arcutis Biotherapeutics Indivior Galapagos Akero Therapeutics Dyne Therapeutics Immunocore Phathom Pharmaceuticals (NASDAQ:PHAT) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment. Do analysts recommend PHAT or IRON? Phathom Pharmaceuticals presently has a consensus target price of $23.00, suggesting a potential upside of 230.46%. Disc Medicine has a consensus target price of $87.50, suggesting a potential upside of 50.24%. Given Phathom Pharmaceuticals' higher probable upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Which has more volatility and risk, PHAT or IRON? Phathom Pharmaceuticals has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Does the media prefer PHAT or IRON? In the previous week, Disc Medicine had 3 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 4 mentions for Disc Medicine and 1 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.00 beat Disc Medicine's score of -0.36 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, PHAT or IRON? Disc Medicine has lower revenue, but higher earnings than Phathom Pharmaceuticals. Disc Medicine is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$680K699.89-$201.59M-$5.69-1.22Disc MedicineN/AN/A-$76.43M-$3.98-14.63 Do insiders and institutionals have more ownership in PHAT or IRON? 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is PHAT or IRON more profitable? Disc Medicine has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-1,292.14% N/A -79.57% Disc Medicine N/A -25.24%-23.96% Does the MarketBeat Community favor PHAT or IRON? Phathom Pharmaceuticals received 39 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 84.75% of users gave Disc Medicine an outperform vote while only 72.36% of users gave Phathom Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPhathom PharmaceuticalsOutperform Votes8972.36% Underperform Votes3427.64% Disc MedicineOutperform Votes5084.75% Underperform Votes915.25% SummaryDisc Medicine beats Phathom Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$474.54M$6.35B$5.22B$8.94BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-1.229.8589.7217.34Price / Sales699.89315.761,251.2178.56Price / CashN/A61.4443.8235.97Price / Book-5.486.055.324.79Net Income-$201.59M$154.90M$122.69M$225.00M7 Day Performance0.29%-1.70%-0.16%1.52%1 Month Performance-12.89%2.72%3.75%4.68%1 Year Performance-8.42%2.83%27.41%20.89% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals2.263 of 5 stars$6.96flat$23.00+230.5%-8.4%$474.54M$680,000.000.00110IRONDisc Medicine2.6011 of 5 stars$58.55-1.2%$87.50+49.4%-6.2%$1.74BN/A-14.7130Short Interest ↑News CoverageBLTEBelite Bio3.2833 of 5 stars$56.00+1.0%$89.00+58.9%+22.6%$1.73BN/A-50.4510Short Interest ↓News CoveragePositive NewsGap UpIBRXImmunityBio2.4081 of 5 stars$2.47+2.1%$13.58+449.9%-19.0%$1.72B$7.33M-2.68590Analyst ForecastOptions VolumeNews CoverageGap UpWVEWave Life Sciences4.8316 of 5 stars$11.04-4.3%$22.22+101.3%+131.4%$1.68B$53.61M-9.95240ARQTArcutis Biotherapeutics2.4653 of 5 stars$13.90+0.7%$16.60+19.4%+287.8%$1.63B$138.71M-7.77150Short Interest ↓Gap UpINDVIndivior2.1062 of 5 stars$11.60-2.1%$16.00+37.9%-24.1%$1.60B$1.18B-289.931,164Short Interest ↑News CoverageGap DownGLPGGalapagos1.3875 of 5 stars$24.23-5.5%$30.75+26.9%-37.2%$1.60B$260.09M0.001,123AKROAkero Therapeutics3.9376 of 5 stars$22.68-8.7%$46.83+106.5%+16.6%$1.58BN/A-6.0530Analyst ForecastNews CoverageDYNDyne Therapeutics3.5673 of 5 stars$14.92-6.0%$49.91+234.5%-12.8%$1.52BN/A-4.19100Analyst ForecastNews CoverageIMCRImmunocore2.5907 of 5 stars$30.07-1.1%$65.64+118.3%-58.2%$1.50B$296.31M-31.65497 Related Companies and Tools Related Companies Disc Medicine Alternatives Belite Bio Alternatives ImmunityBio Alternatives Wave Life Sciences Alternatives Arcutis Biotherapeutics Alternatives Indivior Alternatives Galapagos Alternatives Akero Therapeutics Alternatives Dyne Therapeutics Alternatives Immunocore Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHAT) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAT Stock Alerts